Qprotyn

Qprotyn is a Delaware biotech corporation based in Cambridge, MA and is bringing to market a patented viscosity-reduction, formulation platform called HILOPRO®. HILOPRO® enables high-dose, large molecule monoclonal antibodies to move from IV administration to subcutaneous (SubQ) injection. Using only two GRAS excipients, HILOPRO® delivers low-volume formulations with concentrations greater than 225mg/mL while maintaining a viscosity less than 20 cP. Naturally, this introduces tremendous patient benefits in terms of comfort and convenience and enables innovator and biosimilar mAbs to enhance their marketability. Upgrade your IV mAb to SubQ with Qprotyn | Patients will thank you for getting under their skin!